<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408358</article-id><article-id pub-id-type="pmc">PMC12101646</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0324904</article-id><article-id pub-id-type="publisher-id">PONE-D-24-47478</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Death Rates</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Health Care Facilities</subject><subj-group><subject>Hospitals</subject><subj-group><subject>Intensive Care Units</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Heart Failure</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Sepsis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Transferases</subject><subj-group><subject>Aminotransferases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Enzymes</subject><subj-group><subject>Transferases</subject><subj-group><subject>Aminotransferases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Bioenergetics</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Structures and Organelles</subject><subj-group><subject>Energy-Producing Organelles</subject><subj-group><subject>Mitochondria</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Association between aspartate aminotransferase to alanine aminotransferase ratio and 28-day mortality of ICU patients: A retrospective cohort study from MIMIC-IV database</article-title><alt-title alt-title-type="running-head">AST/ALT ratio and 28-day ICU mortality</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0003-5620-3309</contrib-id><name><surname>Wang</surname><given-names>Yanping</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="cor001" ref-type="corresp">*</xref><xref rid="aff001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Yan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff"/></contrib></contrib-group><aff id="aff001">
<addr-line>Department of Pharmacy, The Affiliated People&#x02019;s Hospital of Ningbo University, Ningbo, Zhejiang, China</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Iqhrammullah</surname><given-names>Muhammad</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Universitas Muhammadiyah Aceh, INDONESIA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>rmwangyanping@nbu.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0324904</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>2</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Wang, Xu</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang, Xu</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0324904.pdf">
</self-uri><abstract><sec id="sec001"><title>Background</title><p>Prior studies have linked the aspartate aminotransferase to alanine aminotransferase ratio (AAR) with negative health outcomes in the elderly and specific populations. However, the impact of AAR on the prognosis of the entire population in the intensive care unit (ICU) remains unclear. This study aimed to determine the correlation between AAR and the mortality among adult ICU patients.</p></sec><sec id="sec002"><title>Method</title><p>Patient data were retrieved from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database and stratified into quartiles by AAR. Survival analysis using the Kaplan-Meier curves was conducted to compare survival across quartiles. The primary outcome was 28-day mortality, with secondary outcomes including 60-day, 90-day, and 365-day mortality, along with ICU-free, ventilator-free, and vasopressor-free days within the first 28 days. The association between AAR and mortality was evaluated using Cox proportional hazards regression analysis complemented by a restricted cubic spline. Furthermore, the eICU Collaborative Research Database (eICU-CRD) was used as an external validation cohort for sensitivity analysis.</p></sec><sec id="sec003"><title>Result</title><p>The study included 20,225 patients with a mean age of 63.7&#x02009;&#x000b1;&#x02009;17.5 years. Kaplan-Meier analysis indicated a higher risk of 28-day mortality for patients with higher AAR (log-rank P&#x02009;&#x0003c;&#x02009;0.001). After adjusting for confounders, the AAR was significantly related to 28-day mortality (HR&#x02009;=&#x02009;1.04, 95% CI: 1.03&#x02013;1.06, P&#x02009;&#x0003c;&#x02009;0.001) and other mortality benchmarks, exhibiting an inverted L-shaped relationship. The inflection point of the AAR for 28-day mortality was 2.60. Below this threshold, each unit increase in the AAR was associated with a 19% rise in the risk of 28-day mortality (HR&#x02009;=&#x02009;1.19, 95% CI: 1.11&#x02013;1.27, P&#x02009;&#x0003c;&#x02009;0.001), with a plateau observed above this threshold. Subgroup and sensitivity analyses further confirmed the robustness and generalizability of the study.</p></sec><sec id="sec004"><title>Conclusion</title><p>AAR demonstrated a significant association with 28-day, 60-day, 90-day, and 365-day mortality, characterized by an inverted L-shaped pattern.</p></sec></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="4"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The data underlying the results presented in the study are available from PhysioNet <ext-link xlink:href="http://doi.org/10.13026/6mm1-ek67" ext-link-type="uri">http://doi.org/10.13026/6mm1-ek67</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The data underlying the results presented in the study are available from PhysioNet <ext-link xlink:href="http://doi.org/10.13026/6mm1-ek67" ext-link-type="uri">http://doi.org/10.13026/6mm1-ek67</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are common indicators used in liver function tests. ALT is specifically located in the cytoplasm of hepatocytes, while AST is found in both the cytoplasm and mitochondria [<xref rid="pone.0324904.ref001" ref-type="bibr">1</xref>]. Initially introduced to diagnose acute viral hepatitis, the AST/ALT ratio (AAR) has become a key biomarker for liver diseases and is significantly linked to poor prognoses in affected individuals [<xref rid="pone.0324904.ref002" ref-type="bibr">2</xref>&#x02013;<xref rid="pone.0324904.ref006" ref-type="bibr">6</xref>]. In contrast to ALT, which is predominantly found in the liver, AST is abundantly present in a variety of tissues such as the liver, heart, muscle, kidney, and brain [<xref rid="pone.0324904.ref001" ref-type="bibr">1</xref>]. Recently, more studies have begun to explore the relationship between AAR and nonliver diseases. High AAR has been linked to an elevated risk of sarcopenia [<xref rid="pone.0324904.ref007" ref-type="bibr">7</xref>]. Another study demonstrated that a high AAR is correlated with increased mortality among elderly populations, exhibiting stronger predictive power for mortality compared to individual AST or ALT levels [<xref rid="pone.0324904.ref008" ref-type="bibr">8</xref>]. Furthermore, elevated AAR has been associated with increased mortality in patients with hypertension, diabetes, sepsis, coronavirus disease of 2019 (COVID-19), heart failure, acute myocardial infarction, coronary artery disease, major burn, traumatic brain injuries, acute ischemic stroke, peripheral arterial occlusive disease, and cancers [<xref rid="pone.0324904.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0324904.ref021" ref-type="bibr">21</xref>].</p><p>ICU patients, at high risk of mortality, often have comorbidities, severe trauma, systemic inflammation, frailty, malnutrition, and sarcopenia [<xref rid="pone.0324904.ref022" ref-type="bibr">22</xref>]. Previous studies have associated elevated AAR with poor outcomes across multiple diseases, but these studies have primarily focused on specific critical conditions or elderly patients [<xref rid="pone.0324904.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0324904.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0324904.ref025" ref-type="bibr">25</xref>]. However, the relationship between AAR and the prognosis of the entire adult population in the ICU remains unclear. This study aims to explore the association between AAR and mortality in adult ICU population, offering a more detailed evaluation of its prognostic potential.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods</title><sec id="sec007"><title>Study design</title><p>We performed a retrospective cohort analysis, utilizing data sourced from the MIMIC-IV database (version 2.2), eliminating the need for the approval of the ethics committee or informed consent of the patient. This comprehensive, high-quality database, developed and sustained by the Massachusetts Institute of Technology, covers deidentified health data from ICU patients at Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. Ethical approval, an informed consent waiver, and research resource sharing approval were granted by the BIDMC Institutional Review Board [<xref rid="pone.0324904.ref026" ref-type="bibr">26</xref>
<xref rid="pone.0324904.ref027" ref-type="bibr">27</xref>]. Access to the database was provided to one of our researchers after completion of the training on protection of human research participants (record ID: 59403724). Our research adhered to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement guidelines for observational studies.</p></sec><sec id="sec008"><title>Study population</title><p>The MIMIC-IV database yielded 73,181 ICU admissions, from which we selected the first instance for patients with recurrent stays, resulting in 50,920 included patients after exclusions. Patients with AST or ALT levels of 0, or missing AST and ALT values on admission day, were excluded. Our final cohort comprised 20,225 patients aged 18 and older, divided into quartile-based groups according to their AAR on the day of ICU admission. The flowchart for patient screening is presented in <xref rid="pone.0324904.g001" ref-type="fig">Fig 1</xref>.</p><fig position="float" id="pone.0324904.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0324904.g001</object-id><label>Fig 1</label><caption><title>Flowchart of the patient selection.</title></caption><graphic xlink:href="pone.0324904.g001" position="float"/></fig></sec><sec id="sec009"><title>Variable extraction</title><p>We sourced data from the MIMIC-IV database, focusing on the initial 24-hour period following ICU admission. This included demographics such as gender, age, weight, race, and marital status, along with lifestyle factors like smoking status. Vital signs recorded were heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), respiratory rate, and SpO2. Laboratory tests encompassed glucose, hemoglobin, platelets, white blood cell (WBC), anion gap, blood urea nitrogen (BUN), creatinine, electrolytes, prothrombin time (PT), AST, and ALT. Clinical scores like the Charlson comorbidity index, Oxford acute severity of illness score (OASIS), and Sequential organ failure assessment (SOFA) were also included. AAR was calculated as AST divided by ALT, with comorbidities identified through the International Classification of Diseases, Ninth Revision (ICD-9) and ICD-10 codes. Sepsis diagnosis adhered to the &#x02018;Third International Consensus Definition for Sepsis and Septic Shock&#x02019;. Furthermore, we extracted information on hospital and ICU stay lengths and patient outcomes, including mortality rates and days without ICU, ventilator, and vasopressor support up to 28 days. All variables included in the analysis had less than 5% missing values.</p></sec><sec id="sec010"><title>Primary outcome and secondary outcomes</title><p>The primary outcome was 28-day mortality. Secondary outcomes were 60-day, 90-day, and 365-day mortality, as well as ICU-free, ventilator-free, and vasopressor-free days within the first 28 days.</p></sec><sec id="sec011"><title>Sensitivity analysis</title><p>To enhance the generalizability of the study, we incorporated an external validation cohort using the eICU-CRD (version 2.0). This multi-center ICU database comprises data from 200,859 ICU admissions across 208 hospitals in the United States between 2014 and 2015. The eICU-CRD is de-identified to ensure patient privacy and has been approved by the Institutional Review Board of the Massachusetts Institute of Technology, with a waiver of informed consent granted [<xref rid="pone.0324904.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0324904.ref029" ref-type="bibr">29</xref>]. Notably, the eICU-CRD follows patients only up to discharge; therefore, 28-day mortality data are unavailable. As a result, we used in-hospital mortality as the outcome for our study. Of the 200,859 ICU admissions in the database, 61,105 patients were included in the final analysis (see <xref rid="pone.0324904.s005" ref-type="supplementary-material">S1 Fig</xref>). Data extracted from the eICU-CRD focused on the first 24 hours after ICU admission, including demographics, vital signs, laboratory data, comorbidities, and severity of illness.</p></sec><sec id="sec012"><title>Statistical analysis</title><p>The baseline characteristics of the participants were delineated based on the quartiles of the AAR. For continuous variables that exhibited a normal distribution, the mean and standard deviation were reported; for those that did not, the median and interquartile range (IQR) were used. Categorical variables were presented in absolute numbers with percentages. Statistical analyses, such as One-way ANOVA, Kruskal-Wallis H test, Chi-square test, or Fisher&#x02019;s exact test, were utilized to compare variations in baseline characteristics among the groups. Multiple imputation was used to replace missing values based on three replications. Additionally, sensitivity analyses were conducted by excluding missing data from the dataset.</p><p>Kaplan-Meier survival curves were constructed and compared across varying AAR groups using the log-rank test. Cox proportional hazard regression models were employed to investigate the association between AAR and mortality, with results expressed as hazard ratios (HR) and 95% confidence intervals (CI). Four models were utilized for result stability verification: Model 1 without covariate adjustments; Model 2 Adjusted for age, gender, weight, race, smoking, and marital status; Model 3 expanded on Model 2 by including heart rate, SBP, DBP, respiratory rate, SpO2, hemoglobin, platelets, WBC, anion gap, BUN, creatinine, potassium, sodium, and PT; Model 4 further adjusted for a broad spectrum of comorbidities and clinical scores. The inclusion of covariates was driven by clinical relevance, significance in univariate analysis (<xref rid="pone.0324904.s001" ref-type="supplementary-material">S1 Table</xref>), and their potential to alter the effect estimate by more than 10%. Multicollinearity was detected using the variance inflation factor (VIF), where a VIF of 5 or higher signaled multicollinearity. Furthermore, a restricted cubic spline (RCS) regression model with four knots was applied to examine the non-linear relationship between AAR and mortality, and a threshold effect analysis was conducted to identify the inflection point. Subgroup analyses were also performed using stratified Cox regression, with interaction assessed via a likelihood ratio test.</p><p>Our statistical procedures were executed with R (Version 4.2.1, <ext-link xlink:href="http://www.R-project.org" ext-link-type="uri">http://www.R-project.org</ext-link>, The R Foundation) alongside the Free Statistics software (Version 1.9.1, <ext-link xlink:href="http://www.clinicalscientists.cn/freestatistics" ext-link-type="uri">http://www.clinicalscientists.cn/freestatistics</ext-link>). Differences with two-sided P&#x02009;&#x0003c;&#x02009;0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec013"><title>Results</title><sec id="sec014"><title>Baseline characteristics</title><p>Our study included 20,225 participants with a mean age of 63.7&#x02009;&#x000b1;&#x02009;17.5 years. Of these, 56.8% were male and 63.5% were white. The median values for AST and ALT were recorded at 45.0 IU/L (25.0, 115.0) and 31.0 IU/L (17.0, 74.0), respectively. By categorizing the participants based on quartiles of AAR at ICU admission (Q1:&#x02009;&#x0003c;&#x02009;1.035, Q2: 1.035&#x02013;1.441, Q3: 1.441&#x02013;2.055, Q4&#x02009;&#x02265;&#x02009;2.056), a detailed analysis of the baseline characteristics of the patients is presented in <xref rid="pone.0324904.t001" ref-type="table">Table 1</xref>. The AAR levels for the four groups were 0.8 (0.6, 0.9), 1.2 (1.1, 1.3), 1.7 (1.6, 1.9), 2.7 (2.3, 3.5), respectively. Compared to the lower group, the highest AAR group exhibited lower body weight, a lower proportion of individuals married, and higher levels of heart rate, respiratory rate, WBC, anion gap, BUN, creatinine, PT, OASIS, and SOFA. They also had lower levels of SBP, DBP, SpO2, glucose, hemoglobin, and platelets. Furthermore, this group had a higher prevalence of myocardial infarction, congestive heart failure, coronary heart disease, sepsis, liver disease, and renal disease, as well as longer hospital and ICU stays. The 28-day, 60-day, 90-day, and 360-day mortality all increased from the Q1 to the Q4 group. In addition, ICU-free, ventilator-free, and vasopressor-free days up to 28 days all decreased from the Q1 to the Q4 group.</p><table-wrap position="float" id="pone.0324904.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0324904.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of patients grouped according to AAR quartiles.</title></caption><alternatives><graphic xlink:href="pone.0324904.t001" id="pone.0324904.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Characteristics</th><th align="left" rowspan="2" colspan="1">Total (n&#x02009;=&#x02009;20255)</th><th align="left" colspan="4" rowspan="1">AAR quartiles</th><th align="left" rowspan="1" colspan="1">P value</th></tr><tr><th align="left" rowspan="1" colspan="1">Q1&#x02009;&#x0003c;&#x02009;1.035 (n&#x02009;=&#x02009;5064)</th><th align="left" rowspan="1" colspan="1">Q2 (1.035&#x02013;1.441) (n&#x02009;=&#x02009;5063)</th><th align="left" rowspan="1" colspan="1">Q3 (1.441&#x02013;2.055) (n&#x02009;=&#x02009;5061)</th><th align="left" rowspan="1" colspan="1">Q4&#x02009;&#x02265;&#x02009;2.056 (n&#x02009;=&#x02009;5067)</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Demographics</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male, n (%)</td><td align="left" rowspan="1" colspan="1">11495 (56.8)</td><td align="left" rowspan="1" colspan="1">3126 (61.7)</td><td align="left" rowspan="1" colspan="1">2810 (55.5)</td><td align="left" rowspan="1" colspan="1">2731 (54)</td><td align="left" rowspan="1" colspan="1">2828 (55.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1">63.7&#x02009;&#x000b1;&#x02009;17.5</td><td align="left" rowspan="1" colspan="1">61.0&#x02009;&#x000b1;&#x02009;17.6</td><td align="left" rowspan="1" colspan="1">64.3&#x02009;&#x000b1;&#x02009;17.6</td><td align="left" rowspan="1" colspan="1">65.3&#x02009;&#x000b1;&#x02009;17.8</td><td align="left" rowspan="1" colspan="1">64.2&#x02009;&#x000b1;&#x02009;16.7</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, Kg</td><td align="left" rowspan="1" colspan="1">82.0&#x02009;&#x000b1;&#x02009;26.4</td><td align="left" rowspan="1" colspan="1">85.4&#x02009;&#x000b1;&#x02009;32.4</td><td align="left" rowspan="1" colspan="1">81.8&#x02009;&#x000b1;&#x02009;25.0</td><td align="left" rowspan="1" colspan="1">80.0&#x02009;&#x000b1;&#x02009;23.1</td><td align="left" rowspan="1" colspan="1">80.7&#x02009;&#x000b1;&#x02009;23.7</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Race, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Non-white</td><td align="left" rowspan="1" colspan="1">7391 (36.5)</td><td align="left" rowspan="1" colspan="1">1795 (35.4)</td><td align="left" rowspan="1" colspan="1">1794 (35.4)</td><td align="left" rowspan="1" colspan="1">1866 (36.9)</td><td align="left" rowspan="1" colspan="1">1936 (38.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;White</td><td align="left" rowspan="1" colspan="1">12864 (63.5)</td><td align="left" rowspan="1" colspan="1">3269 (64.6)</td><td align="left" rowspan="1" colspan="1">3269 (64.6)</td><td align="left" rowspan="1" colspan="1">3195 (63.1)</td><td align="left" rowspan="1" colspan="1">3131 (61.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Marital status, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Married</td><td align="left" rowspan="1" colspan="1">8339 (41.2)</td><td align="left" rowspan="1" colspan="1">2208 (43.6)</td><td align="left" rowspan="1" colspan="1">2134 (42.1)</td><td align="left" rowspan="1" colspan="1">2010 (39.7)</td><td align="left" rowspan="1" colspan="1">1987 (39.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Others</td><td align="left" rowspan="1" colspan="1">11916 (58.8)</td><td align="left" rowspan="1" colspan="1">2856 (56.4)</td><td align="left" rowspan="1" colspan="1">2929 (57.9)</td><td align="left" rowspan="1" colspan="1">3051 (60.3)</td><td align="left" rowspan="1" colspan="1">3080 (60.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, n (%)</td><td align="left" rowspan="1" colspan="1">3515 (17.4)</td><td align="left" rowspan="1" colspan="1">858 (16.9)</td><td align="left" rowspan="1" colspan="1">892 (17.6)</td><td align="left" rowspan="1" colspan="1">924 (18.3)</td><td align="left" rowspan="1" colspan="1">841 (16.6)</td><td align="left" rowspan="1" colspan="1">0.125</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Vital signs</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate, bpm</td><td align="left" rowspan="1" colspan="1">86.9&#x02009;&#x000b1;&#x02009;17.1</td><td align="left" rowspan="1" colspan="1">86.5&#x02009;&#x000b1;&#x02009;17.4</td><td align="left" rowspan="1" colspan="1">85.9&#x02009;&#x000b1;&#x02009;17.3</td><td align="left" rowspan="1" colspan="1">86.7&#x02009;&#x000b1;&#x02009;16.8</td><td align="left" rowspan="1" colspan="1">88.6&#x02009;&#x000b1;&#x02009;16.9</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP, mmHg</td><td align="left" rowspan="1" colspan="1">118.1&#x02009;&#x000b1;&#x02009;17.4</td><td align="left" rowspan="1" colspan="1">120.1&#x02009;&#x000b1;&#x02009;17.1</td><td align="left" rowspan="1" colspan="1">119.6&#x02009;&#x000b1;&#x02009;17.4</td><td align="left" rowspan="1" colspan="1">117.9&#x02009;&#x000b1;&#x02009;17.6</td><td align="left" rowspan="1" colspan="1">114.7&#x02009;&#x000b1;&#x02009;16.9</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">DPB, mmHg</td><td align="left" rowspan="1" colspan="1">64.9&#x02009;&#x000b1;&#x02009;11.8</td><td align="left" rowspan="1" colspan="1">67.0&#x02009;&#x000b1;&#x02009;11.7</td><td align="left" rowspan="1" colspan="1">65.4&#x02009;&#x000b1;&#x02009;11.7</td><td align="left" rowspan="1" colspan="1">64.1&#x02009;&#x000b1;&#x02009;11.8</td><td align="left" rowspan="1" colspan="1">63.0&#x02009;&#x000b1;&#x02009;11.7</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory rate, bpm</td><td align="left" rowspan="1" colspan="1">19.8&#x02009;&#x000b1;&#x02009;4.1</td><td align="left" rowspan="1" colspan="1">19.7&#x02009;&#x000b1;&#x02009;3.9</td><td align="left" rowspan="1" colspan="1">19.6&#x02009;&#x000b1;&#x02009;4.0</td><td align="left" rowspan="1" colspan="1">19.7&#x02009;&#x000b1;&#x02009;4.0</td><td align="left" rowspan="1" colspan="1">20.1&#x02009;&#x000b1;&#x02009;4.3</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SpO2, %</td><td align="left" rowspan="1" colspan="1">91.2&#x02009;&#x000b1;&#x02009;7.5</td><td align="left" rowspan="1" colspan="1">91.6&#x02009;&#x000b1;&#x02009;5.9</td><td align="left" rowspan="1" colspan="1">91.6&#x02009;&#x000b1;&#x02009;6.3</td><td align="left" rowspan="1" colspan="1">91.0&#x02009;&#x000b1;&#x02009;8.1</td><td align="left" rowspan="1" colspan="1">90.6&#x02009;&#x000b1;&#x02009;9.1</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Laboratory data</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Glucose, mg/dL</td><td align="left" rowspan="1" colspan="1">128.1 (106.5, 162.0)</td><td align="left" rowspan="1" colspan="1">128.0 (107.9, 166.2)</td><td align="left" rowspan="1" colspan="1">130.0 (106.5, 163.8)</td><td align="left" rowspan="1" colspan="1">128.0 (106.0, 161.3)</td><td align="left" rowspan="1" colspan="1">126.9 (105.7, 157.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin, g/dL</td><td align="left" rowspan="1" colspan="1">10.2&#x02009;&#x000b1;&#x02009;2.4</td><td align="left" rowspan="1" colspan="1">10.8&#x02009;&#x000b1;&#x02009;2.4</td><td align="left" rowspan="1" colspan="1">10.5&#x02009;&#x000b1;&#x02009;2.3</td><td align="left" rowspan="1" colspan="1">10.0&#x02009;&#x000b1;&#x02009;2.3</td><td align="left" rowspan="1" colspan="1">9.6&#x02009;&#x000b1;&#x02009;2.3</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelets, K/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">170.0 (111.0, 233.0)</td><td align="left" rowspan="1" colspan="1">189.0 (135.0, 251.0)</td><td align="left" rowspan="1" colspan="1">179.0 (123.0, 240.0)</td><td align="left" rowspan="1" colspan="1">164.0 (109.0, 229.0)</td><td align="left" rowspan="1" colspan="1">143.0 (83.0, 208.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC, K/&#x000b5;L</td><td align="left" rowspan="1" colspan="1">12.3 (8.6, 17.5)</td><td align="left" rowspan="1" colspan="1">12.0 (8.5, 16.8)</td><td align="left" rowspan="1" colspan="1">11.9 (8.4, 16.8)</td><td align="left" rowspan="1" colspan="1">12.5 (8.6, 17.7)</td><td align="left" rowspan="1" colspan="1">12.8 (8.8, 18.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Anion gap, mmol/L</td><td align="left" rowspan="1" colspan="1">17.5&#x02009;&#x000b1;&#x02009;5.5</td><td align="left" rowspan="1" colspan="1">16.7&#x02009;&#x000b1;&#x02009;4.8</td><td align="left" rowspan="1" colspan="1">17.1&#x02009;&#x000b1;&#x02009;5.3</td><td align="left" rowspan="1" colspan="1">17.5&#x02009;&#x000b1;&#x02009;5.5</td><td align="left" rowspan="1" colspan="1">18.5&#x02009;&#x000b1;&#x02009;6.2</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN, mg/dL</td><td align="left" rowspan="1" colspan="1">22.0 (14.0, 37.0)</td><td align="left" rowspan="1" colspan="1">21.0 (14.0, 35.0)</td><td align="left" rowspan="1" colspan="1">21.0 (14.0, 35.0)</td><td align="left" rowspan="1" colspan="1">23.0 (15.0, 38.0)</td><td align="left" rowspan="1" colspan="1">25.0 (15.0, 41.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine, mg/dL</td><td align="left" rowspan="1" colspan="1">1.1 (0.8, 1.8)</td><td align="left" rowspan="1" colspan="1">1.0 (0.8, 1.6)</td><td align="left" rowspan="1" colspan="1">1.1 (0.8, 1.6)</td><td align="left" rowspan="1" colspan="1">1.1 (0.8, 1.8)</td><td align="left" rowspan="1" colspan="1">1.3 (0.9, 2.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium, mg/dL</td><td align="left" rowspan="1" colspan="1">8.6&#x02009;&#x000b1;&#x02009;1.0</td><td align="left" rowspan="1" colspan="1">8.6&#x02009;&#x000b1;&#x02009;0.9</td><td align="left" rowspan="1" colspan="1">8.6&#x02009;&#x000b1;&#x02009;0.9</td><td align="left" rowspan="1" colspan="1">8.6&#x02009;&#x000b1;&#x02009;1.0</td><td align="left" rowspan="1" colspan="1">8.6&#x02009;&#x000b1;&#x02009;1.0</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Potassium, mmol/L</td><td align="left" rowspan="1" colspan="1">4.6&#x02009;&#x000b1;&#x02009;0.9</td><td align="left" rowspan="1" colspan="1">4.5&#x02009;&#x000b1;&#x02009;0.8</td><td align="left" rowspan="1" colspan="1">4.6&#x02009;&#x000b1;&#x02009;0.9</td><td align="left" rowspan="1" colspan="1">4.6&#x02009;&#x000b1;&#x02009;0.9</td><td align="left" rowspan="1" colspan="1">4.7&#x02009;&#x000b1;&#x02009;1.0</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Chloride, mmol/L</td><td align="left" rowspan="1" colspan="1">105.6&#x02009;&#x000b1;&#x02009;6.6</td><td align="left" rowspan="1" colspan="1">105.5&#x02009;&#x000b1;&#x02009;6.4</td><td align="left" rowspan="1" colspan="1">105.8&#x02009;&#x000b1;&#x02009;6.4</td><td align="left" rowspan="1" colspan="1">105.8&#x02009;&#x000b1;&#x02009;6.6</td><td align="left" rowspan="1" colspan="1">105.2&#x02009;&#x000b1;&#x02009;7.1</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium, mmol/L</td><td align="left" rowspan="1" colspan="1">139.9&#x02009;&#x000b1;&#x02009;5.3</td><td align="left" rowspan="1" colspan="1">140.1&#x02009;&#x000b1;&#x02009;5.1</td><td align="left" rowspan="1" colspan="1">140.1&#x02009;&#x000b1;&#x02009;5.1</td><td align="left" rowspan="1" colspan="1">139.8&#x02009;&#x000b1;&#x02009;5.3</td><td align="left" rowspan="1" colspan="1">139.4&#x02009;&#x000b1;&#x02009;5.7</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">PT, s</td><td align="left" rowspan="1" colspan="1">14.5 (12.7, 18.4)</td><td align="left" rowspan="1" colspan="1">14.0 (12.4, 16.6)</td><td align="left" rowspan="1" colspan="1">14.1 (12.4, 17.3)</td><td align="left" rowspan="1" colspan="1">14.7 (12.7, 18.6)</td><td align="left" rowspan="1" colspan="1">15.7 (13.2, 20.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT, IU/L</td><td align="left" rowspan="1" colspan="1">31.0 (17.0, 74.0)</td><td align="left" rowspan="1" colspan="1">50.0 (28.0, 123.0)</td><td align="left" rowspan="1" colspan="1">28.0 (17.0, 64.0)</td><td align="left" rowspan="1" colspan="1">24.0 (15.0, 54.0)</td><td align="left" rowspan="1" colspan="1">26.0 (14.0, 59.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">AST, IU/L</td><td align="left" rowspan="1" colspan="1">45.0 (25.0, 115.0)</td><td align="left" rowspan="1" colspan="1">38.0 (22.0, 87.0)</td><td align="left" rowspan="1" colspan="1">35.0 (22.0, 81.0)</td><td align="left" rowspan="1" colspan="1">42.0 (25.0, 99.0)</td><td align="left" rowspan="1" colspan="1">78.0 (39.0, 198.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">AST/ALT ratio</td><td align="left" rowspan="1" colspan="1">1.4 (1.0, 2.1)</td><td align="left" rowspan="1" colspan="1">0.8 (0.6, 0.9)</td><td align="left" rowspan="1" colspan="1">1.2 (1.1, 1.3)</td><td align="left" rowspan="1" colspan="1">1.7 (1.6, 1.9)</td><td align="left" rowspan="1" colspan="1">2.7 (2.3, 3.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Comorbidities, n (%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarct</td><td align="left" rowspan="1" colspan="1">3428 (16.9)</td><td align="left" rowspan="1" colspan="1">671 (13.3)</td><td align="left" rowspan="1" colspan="1">736 (14.5)</td><td align="left" rowspan="1" colspan="1">851 (16.8)</td><td align="left" rowspan="1" colspan="1">1170 (23.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Congestive heart failure</td><td align="left" rowspan="1" colspan="1">5393 (26.6)</td><td align="left" rowspan="1" colspan="1">1296 (25.6)</td><td align="left" rowspan="1" colspan="1">1283 (25.3)</td><td align="left" rowspan="1" colspan="1">1366 (27)</td><td align="left" rowspan="1" colspan="1">1448 (28.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary heart disease</td><td align="left" rowspan="1" colspan="1">2182 (10.8)</td><td align="left" rowspan="1" colspan="1">440 (8.7)</td><td align="left" rowspan="1" colspan="1">515 (10.2)</td><td align="left" rowspan="1" colspan="1">548 (10.8)</td><td align="left" rowspan="1" colspan="1">679 (13.4)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">3828 (18.9)</td><td align="left" rowspan="1" colspan="1">888 (17.5)</td><td align="left" rowspan="1" colspan="1">990 (19.6)</td><td align="left" rowspan="1" colspan="1">987 (19.5)</td><td align="left" rowspan="1" colspan="1">963 (19)</td><td align="left" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" rowspan="1" colspan="1">Peripheral vascular disease</td><td align="left" rowspan="1" colspan="1">2018 (10.0)</td><td align="left" rowspan="1" colspan="1">416 (8.2)</td><td align="left" rowspan="1" colspan="1">494 (9.8)</td><td align="left" rowspan="1" colspan="1">556 (11)</td><td align="left" rowspan="1" colspan="1">552 (10.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Cerebrovascular disease</td><td align="left" rowspan="1" colspan="1">2964 (14.6)</td><td align="left" rowspan="1" colspan="1">722 (14.3)</td><td align="left" rowspan="1" colspan="1">861 (17)</td><td align="left" rowspan="1" colspan="1">740 (14.6)</td><td align="left" rowspan="1" colspan="1">641 (12.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Dementia</td><td align="left" rowspan="1" colspan="1">768 (3.8)</td><td align="left" rowspan="1" colspan="1">183 (3.6)</td><td align="left" rowspan="1" colspan="1">204 (4)</td><td align="left" rowspan="1" colspan="1">197 (3.9)</td><td align="left" rowspan="1" colspan="1">184 (3.6)</td><td align="left" rowspan="1" colspan="1">0.632</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic pulmonary disease</td><td align="left" rowspan="1" colspan="1">4797 (23.7)</td><td align="left" rowspan="1" colspan="1">1258 (24.8)</td><td align="left" rowspan="1" colspan="1">1178 (23.3)</td><td align="left" rowspan="1" colspan="1">1219 (24.1)</td><td align="left" rowspan="1" colspan="1">1142 (22.5)</td><td align="left" rowspan="1" colspan="1">0.039</td></tr><tr><td align="left" rowspan="1" colspan="1">Rheumatic disease</td><td align="left" rowspan="1" colspan="1">662 (3.3)</td><td align="left" rowspan="1" colspan="1">147 (2.9)</td><td align="left" rowspan="1" colspan="1">137 (2.7)</td><td align="left" rowspan="1" colspan="1">200 (4)</td><td align="left" rowspan="1" colspan="1">178 (3.5)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver disease</td><td align="left" rowspan="1" colspan="1">4197 (20.7)</td><td align="left" rowspan="1" colspan="1">698 (13.8)</td><td align="left" rowspan="1" colspan="1">820 (16.2)</td><td align="left" rowspan="1" colspan="1">1087 (21.5)</td><td align="left" rowspan="1" colspan="1">1592 (31.4)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal disease</td><td align="left" rowspan="1" colspan="1">3938 (19.4)</td><td align="left" rowspan="1" colspan="1">868 (17.1)</td><td align="left" rowspan="1" colspan="1">967 (19.1)</td><td align="left" rowspan="1" colspan="1">1046 (20.7)</td><td align="left" rowspan="1" colspan="1">1057 (20.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">12151 (60.0)</td><td align="left" rowspan="1" colspan="1">2983 (58.9)</td><td align="left" rowspan="1" colspan="1">3105 (61.3)</td><td align="left" rowspan="1" colspan="1">3089 (61)</td><td align="left" rowspan="1" colspan="1">2974 (58.7)</td><td align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1">5734 (28.3)</td><td align="left" rowspan="1" colspan="1">1506 (29.7)</td><td align="left" rowspan="1" colspan="1">1499 (29.6)</td><td align="left" rowspan="1" colspan="1">1410 (27.9)</td><td align="left" rowspan="1" colspan="1">1319 (26)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis</td><td align="left" rowspan="1" colspan="1">11332 (55.9)</td><td align="left" rowspan="1" colspan="1">2535 (50.1)</td><td align="left" rowspan="1" colspan="1">2671 (52.8)</td><td align="left" rowspan="1" colspan="1">2895 (57.2)</td><td align="left" rowspan="1" colspan="1">3231 (63.8)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Severity of illness</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Charlson comorbidity index</td><td align="left" rowspan="1" colspan="1">6.0 (3.0, 8.0)</td><td align="left" rowspan="1" colspan="1">5.0 (3.0, 7.0)</td><td align="left" rowspan="1" colspan="1">5.0 (3.0, 7.0)</td><td align="left" rowspan="1" colspan="1">6.0 (4.0, 8.0)</td><td align="left" rowspan="1" colspan="1">6.0 (4.0, 8.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">OASIS</td><td align="left" rowspan="1" colspan="1">33.0&#x02009;&#x000b1;&#x02009;9.7</td><td align="left" rowspan="1" colspan="1">30.7&#x02009;&#x000b1;&#x02009;9.1</td><td align="left" rowspan="1" colspan="1">32.4&#x02009;&#x000b1;&#x02009;9.3</td><td align="left" rowspan="1" colspan="1">33.8&#x02009;&#x000b1;&#x02009;9.7</td><td align="left" rowspan="1" colspan="1">35.2&#x02009;&#x000b1;&#x02009;10.1</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">SOFA</td><td align="left" rowspan="1" colspan="1">4.0 (2.0, 7.0)</td><td align="left" rowspan="1" colspan="1">4.0 (2.0, 6.0)</td><td align="left" rowspan="1" colspan="1">4.0 (2.0, 7.0)</td><td align="left" rowspan="1" colspan="1">5.0 (2.0, 8.0)</td><td align="left" rowspan="1" colspan="1">6.0 (3.0, 9.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Length of stay (LOS)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">LOS in hospital, days</td><td align="left" rowspan="1" colspan="1">7.4 (4.1, 13.6)</td><td align="left" rowspan="1" colspan="1">6.8 (3.9, 12.4)</td><td align="left" rowspan="1" colspan="1">7.0 (3.9, 12.7)</td><td align="left" rowspan="1" colspan="1">7.7 (4.2, 13.9)</td><td align="left" rowspan="1" colspan="1">8.2 (4.6, 15.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">LOS in ICU, days</td><td align="left" rowspan="1" colspan="1">2.2 (1.2, 4.5)</td><td align="left" rowspan="1" colspan="1">2.0 (1.1, 3.9)</td><td align="left" rowspan="1" colspan="1">2.1 (1.1, 4.1)</td><td align="left" rowspan="1" colspan="1">2.2 (1.2, 4.7)</td><td align="left" rowspan="1" colspan="1">2.6 (1.4, 5.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Outcomes</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">28-day mortality, n (%)</td><td align="left" rowspan="1" colspan="1">3889 (19.2)</td><td align="left" rowspan="1" colspan="1">631 (12.5)</td><td align="left" rowspan="1" colspan="1">776 (15.3)</td><td align="left" rowspan="1" colspan="1">1078 (21.3)</td><td align="left" rowspan="1" colspan="1">1404 (27.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">60-day mortality, n (%)</td><td align="left" rowspan="1" colspan="1">4675 (23.1)</td><td align="left" rowspan="1" colspan="1">792 (15.6)</td><td align="left" rowspan="1" colspan="1">974 (19.2)</td><td align="left" rowspan="1" colspan="1">1285 (25.4)</td><td align="left" rowspan="1" colspan="1">1624 (32.1)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">90-day mortality, n (%)</td><td align="left" rowspan="1" colspan="1">5114 (25.2)</td><td align="left" rowspan="1" colspan="1">898 (17.7)</td><td align="left" rowspan="1" colspan="1">1086 (21.4)</td><td align="left" rowspan="1" colspan="1">1387 (27.4)</td><td align="left" rowspan="1" colspan="1">1743 (34.4)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">360-day mortality, n (%)</td><td align="left" rowspan="1" colspan="1">6691 (33.0)</td><td align="left" rowspan="1" colspan="1">1277 (25.2)</td><td align="left" rowspan="1" colspan="1">1469 (29.0)</td><td align="left" rowspan="1" colspan="1">1788 (35.3)</td><td align="left" rowspan="1" colspan="1">2157 (42.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU-free days up to 28 days</td><td align="left" rowspan="1" colspan="1">25.2 (16.9, 26.6)</td><td align="left" rowspan="1" colspan="1">25.8 (22.4, 26.8)</td><td align="left" rowspan="1" colspan="1">25.5 (20.9, 26.7)</td><td align="left" rowspan="1" colspan="1">25.0 (13.2, 26.5)</td><td align="left" rowspan="1" colspan="1">23.8 (0.0, 26.2)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Ventilator-free days up to 28 days</td><td align="left" rowspan="1" colspan="1">28.0 (23.9, 28.0)</td><td align="left" rowspan="1" colspan="1">28.0 (27.0, 28.0)</td><td align="left" rowspan="1" colspan="1">28.0 (26.1, 28.0)</td><td align="left" rowspan="1" colspan="1">27.8 (21.5, 28.0)</td><td align="left" rowspan="1" colspan="1">27.3 (0.0, 28.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Vasopressor-free days up to 28 days</td><td align="left" rowspan="1" colspan="1">28.0 (25.0, 28.0)</td><td align="left" rowspan="1" colspan="1">28.0 (27.4, 28.0)</td><td align="left" rowspan="1" colspan="1">28.0 (26.7, 28.0)</td><td align="left" rowspan="1" colspan="1">28.0 (23.4, 28.0)</td><td align="left" rowspan="1" colspan="1">27.8 (0.0, 28.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Notes: Continuous variables are presented as mean&#x02009;&#x000b1;&#x02009;SD if normally distributed, and median (IQR) if not normally distributed. Categorical variables are presented as n (%). Abbreviations: Q, quartile; bpm, beats per minute; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; BUN, blood urea nitrogen; PT, prothrombin time; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SOFA, sequential organ failure assessment; OASIS, Oxford acute severity of illness score.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec015"><title>Survival analysis</title><p>The Kaplan-Meier survival curves presented in <xref rid="pone.0324904.g002" ref-type="fig">Fig 2</xref> reveal the link between the AAR quartiles and 28-day mortality. The mortality rates showed a statistically significant gradual increase from the Q1 to the Q4 groups (Q1: 12.5% vs. Q2: 15.3% vs. Q3: 21.3% vs. Q4: 27.7%, P&#x02009;&#x0003c;&#x02009;0.0001). It is significant to note that patients with a higher AAR are at an elevated risk of mortality within the first 28 days.</p><fig position="float" id="pone.0324904.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0324904.g002</object-id><label>Fig 2</label><caption><title>Kaplan-Meier survival analysis curves of 28-day mortality by AAR.</title></caption><graphic xlink:href="pone.0324904.g002" position="float"/></fig></sec><sec id="sec016"><title>AAR and clinical outcomes</title><p>To ascertain the independent impact of AAR on 28-day mortality, four Cox proportional hazard models were utilized, as detailed in <xref rid="pone.0324904.t002" ref-type="table">Table 2</xref>. In the unadjusted model 1, AAR exhibited a positive association with 28-day mortality (HR&#x02009;=&#x02009;1.1, 95% CI: 1.09&#x02013;1.10, P&#x02009;&#x0003c;&#x02009;0.001). This link persisted in the subsequent adjusted models: Model 2 (HR&#x02009;=&#x02009;1.1, 95% CI: 1.09&#x02013;1.11), Model 3 (HR&#x02009;=&#x02009;1.07, 95% CI: 1.06&#x02013;1.09), and Model 4 (HR&#x02009;=&#x02009;1.04, 95% CI: 1.03&#x02013;1.06), each with a P-value below 0.001.</p><table-wrap position="float" id="pone.0324904.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0324904.t002</object-id><label>Table 2</label><caption><title>Cox model analysis of AAR and 28-day mortality.</title></caption><alternatives><graphic xlink:href="pone.0324904.t002" id="pone.0324904.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" colspan="2" rowspan="1">Model 1</th><th align="left" colspan="2" rowspan="1">Model 2</th><th align="left" colspan="2" rowspan="1">Model 3</th><th align="left" colspan="2" rowspan="1">Model 4</th></tr><tr><th align="left" rowspan="1" colspan="1">HR(95%)</th><th align="left" rowspan="1" colspan="1">P value</th><th align="left" rowspan="1" colspan="1">HR(95%)</th><th align="left" rowspan="1" colspan="1">P value</th><th align="left" rowspan="1" colspan="1">HR(95%)</th><th align="left" rowspan="1" colspan="1">P value</th><th align="left" rowspan="1" colspan="1">HR(95%)</th><th align="left" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AAR</td><td align="left" rowspan="1" colspan="1">1.1 (1.09&#x02009;~&#x02009;1.10)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.1 (1.09&#x02009;~&#x02009;1.11)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.07 (1.06&#x02009;~&#x02009;1.09)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.04 (1.03&#x02009;~&#x02009;1.06)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">AAR quartiles</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Q1 &#x0003c; &#x02009;1.035</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Q2 (1.035&#x02013;1.441)</td><td align="left" rowspan="1" colspan="1">1.26 (1.13&#x02009;~&#x02009;1.40)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.16 (1.05&#x02009;~&#x02009;1.29)</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">1.13 (1.02&#x02009;~&#x02009;1.26)</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">1.08 (0.97&#x02009;~&#x02009;1.20)</td><td align="left" rowspan="1" colspan="1">0.158</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Q3 (1.441&#x02013;2.055)</td><td align="left" rowspan="1" colspan="1">1.81 (1.64&#x02009;~&#x02009;2.00)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.63 (1.48&#x02009;~&#x02009;1.80)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.43 (1.29&#x02009;~&#x02009;1.58)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.29 (1.17&#x02009;~&#x02009;1.43)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Q4&#x02009;&#x02265;&#x02009;2.056</td><td align="left" rowspan="1" colspan="1">2.46 (2.24&#x02009;~&#x02009;2.70)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">2.28 (2.07&#x02009;~&#x02009;2.50)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.71 (1.55&#x02009;~&#x02009;1.88)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">1.41 (1.28&#x02009;~&#x02009;1.56)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Model 1: no covariates were adjusted.</p></fn><fn id="t002fn002"><p>Model 2: adjusted for age, gender, weight, race, smoking, and marital status.</p></fn><fn id="t002fn003"><p>Model 3: adjusted for mode 2&#x02009;+&#x02009;heart rate, SBP, DBP, Respiratory rate, SpO2, hemoglobin, platelets, WBC, aniongap, bun, creatinine, potassium, sodium, and PT.</p></fn><fn id="t002fn004"><p>Model 4: adjusted for mode 3&#x02009;+&#x02009;myocardial infarct, congestive heart failure, atrial fibrillation, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, liver disease, renal disease, hypertension, diabetes, sepsis, Charlson comorbidity index, OASIS, and SOFA.</p></fn></table-wrap-foot></table-wrap><p>For sensitivity analysis, AAR was categorized into quartiles, using Q1 serving as the reference group. In Model 4, the risk of 28-day mortality increased by 8%, 29%, and 41% for patients in Q2, Q3, and Q4, respectively (HR&#x02009;=&#x02009;1.08, 95% CI: 0.97&#x02013;1.20, P&#x02009;=&#x02009;0.158; HR&#x02009;=&#x02009;1.29, 95% CI: 1.17&#x02013;1.43, P&#x02009;&#x0003c;&#x02009;0.001; HR&#x02009;=&#x02009;1.41, 95% CI: 1.28&#x02013;1.56, P&#x02009;&#x0003c;&#x02009;0.001). Additionally, the results remained consistent after the exclusion of 2447 patients, who constituted 12.1% of the total sample and had missing data, as detailed in the <xref rid="pone.0324904.s002" ref-type="supplementary-material">S2 Table</xref>.</p><p><xref rid="pone.0324904.t003" ref-type="table">Table 3</xref> presents secondary outcomes, indicating that an elevated AAR was linked to increased 60-day, 90-day, and 365-day mortality, and reduced days free from ICU, ventilator, and vasopressor support within the first 28 days.</p><table-wrap position="float" id="pone.0324904.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0324904.t003</object-id><label>Table 3</label><caption><title>Association between AAR and secondary outcome.</title></caption><alternatives><graphic xlink:href="pone.0324904.t003" id="pone.0324904.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">Variable</th><th align="left" colspan="5" rowspan="1">Coefficient (95%CI)</th></tr><tr><th align="left" rowspan="2" colspan="1">AAR continuous</th><th align="left" colspan="4" rowspan="1">AAR quartiles</th></tr><tr><th align="left" rowspan="1" colspan="1">Q1&#x02009;&#x0003c;&#x02009;1.035</th><th align="left" rowspan="1" colspan="1">Q2 (1.035&#x02013;1.441)</th><th align="left" rowspan="1" colspan="1">Q3 (1.441&#x02013;2.055)</th><th align="left" rowspan="1" colspan="1">Q4&#x02009;&#x02265;&#x02009;2.056</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">
<bold>60-day mortality</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Crude</td><td align="left" rowspan="1" colspan="1">1.1 (1.09&#x02009;~&#x02009;1.11)</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1">1.26 (1.15&#x02009;~&#x02009;1.39)</td><td align="left" rowspan="1" colspan="1">1.74 (1.59&#x02009;~&#x02009;1.9)</td><td align="left" rowspan="1" colspan="1">2.31 (2.12&#x02009;~&#x02009;2.51)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Adjusted<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">1.05 (1.03&#x02009;~&#x02009;1.06)</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1">1.09 (1&#x02009;~&#x02009;1.2)</td><td align="left" rowspan="1" colspan="1">1.25 (1.14&#x02009;~&#x02009;1.37)</td><td align="left" rowspan="1" colspan="1">1.37 (1.26&#x02009;~&#x02009;1.5)</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>90-day mortality</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Crude</td><td align="left" rowspan="1" colspan="1">1.1 (1.09&#x02009;~&#x02009;1.1)</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1">1.24 (1.14&#x02009;~&#x02009;1.36)</td><td align="left" rowspan="1" colspan="1">1.66 (1.53&#x02009;~&#x02009;1.81)</td><td align="left" rowspan="1" colspan="1">2.2 (2.03&#x02009;~&#x02009;2.39)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Adjusted<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">1.04 (1.03&#x02009;~&#x02009;1.06)</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1">1.08 (0.99&#x02009;~&#x02009;1.19)</td><td align="left" rowspan="1" colspan="1">1.21 (1.11&#x02009;~&#x02009;1.31)</td><td align="left" rowspan="1" colspan="1">1.34 (1.23&#x02009;~&#x02009;1.45)</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>365-day mortality</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Crude</td><td align="left" rowspan="1" colspan="1">1.09 (1.09&#x02009;~&#x02009;1.1)</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1">1.19 (1.1&#x02009;~&#x02009;1.28)</td><td align="left" rowspan="1" colspan="1">1.53 (1.43&#x02009;~&#x02009;1.65)</td><td align="left" rowspan="1" colspan="1">1.97 (1.84&#x02009;~&#x02009;2.11)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Adjusted<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">1.04 (1.03&#x02009;~&#x02009;1.06)</td><td align="left" rowspan="1" colspan="1">1 (Reference)</td><td align="left" rowspan="1" colspan="1">1.06 (0.98&#x02009;~&#x02009;1.14)</td><td align="left" rowspan="1" colspan="1">1.14 (1.06&#x02009;~&#x02009;1.23)</td><td align="left" rowspan="1" colspan="1">1.27 (1.18&#x02009;~&#x02009;1.37)</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>Vasopressor-free days up to 28 days</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Crude</td><td align="left" rowspan="1" colspan="1">-1.28 (-1.4&#x02009;~&#x02009;-1.16)</td><td align="left" rowspan="1" colspan="1">0 (Reference)</td><td align="left" rowspan="1" colspan="1">-0.81 (-1.23&#x02009;~&#x02009;-0.39)</td><td align="left" rowspan="1" colspan="1">-2.57 (-2.99&#x02009;~&#x02009;-2.14)</td><td align="left" rowspan="1" colspan="1">-4.65 (-5.07&#x02009;~&#x02009;-4.23)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Adjusted<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">-0.37 (-0.48&#x02009;~&#x02009;-0.27)</td><td align="left" rowspan="1" colspan="1">0 (Reference)</td><td align="left" rowspan="1" colspan="1">0.1 (-0.26&#x02009;~&#x02009;0.46)</td><td align="left" rowspan="1" colspan="1">-0.52 (-0.89&#x02009;~&#x02009;-0.16)</td><td align="left" rowspan="1" colspan="1">-1.21 (-1.59&#x02009;~&#x02009;-0.83)</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>ICU-free days up to 28 days</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Crude</td><td align="left" rowspan="1" colspan="1">-1.24 (-1.35&#x02009;~&#x02009;-1.13)</td><td align="left" rowspan="1" colspan="1">0 (Reference)</td><td align="left" rowspan="1" colspan="1">-0.81 (-1.21&#x02009;~&#x02009;-0.41)</td><td align="left" rowspan="1" colspan="1">-2.55 (-2.95&#x02009;~&#x02009;-2.14)</td><td align="left" rowspan="1" colspan="1">-4.55 (-4.95&#x02009;~&#x02009;-4.15)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Adjusted<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">-0.36 (-0.45&#x02009;~&#x02009;-0.26)</td><td align="left" rowspan="1" colspan="1">0 (Reference)</td><td align="left" rowspan="1" colspan="1">0.09 (-0.25&#x02009;~&#x02009;0.42)</td><td align="left" rowspan="1" colspan="1">-0.57 (-0.9&#x02009;~&#x02009;-0.23)</td><td align="left" rowspan="1" colspan="1">-1.2 (-1.55&#x02009;~&#x02009;-0.85)</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>Ventilator-free days up to 28 days</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Crude</td><td align="left" rowspan="1" colspan="1">-1.25 (-1.37&#x02009;~&#x02009;-1.14)</td><td align="left" rowspan="1" colspan="1">0 (Reference)</td><td align="left" rowspan="1" colspan="1">-0.85 (-1.27&#x02009;~&#x02009;-0.43)</td><td align="left" rowspan="1" colspan="1">-2.64 (-3.06&#x02009;~&#x02009;-2.22)</td><td align="left" rowspan="1" colspan="1">-4.58 (-5&#x02009;~&#x02009;-4.16)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Adjusted<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">-0.37 (-0.47&#x02009;~&#x02009;-0.27)</td><td align="left" rowspan="1" colspan="1">0 (Reference)</td><td align="left" rowspan="1" colspan="1">0.04 (-0.32&#x02009;~&#x02009;0.4)</td><td align="left" rowspan="1" colspan="1">-0.64 (-1.01&#x02009;~&#x02009;-0.28)</td><td align="left" rowspan="1" colspan="1">-1.24 (-1.62&#x02009;~&#x02009;-0.86)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><sup>a</sup>Adjusted for all factors in Model 4 (age, gender, weight, race, smoking, marital status, heart rate, SBP, DBP, Respiratory rate, SpO2, hemoglobin, platelets, WBC, aniongap, bun, creatinine, potassium, sodium, PT, myocardial infarct, congestive heart failure, atrial fibrillation, peripheral vascular disease, cerebrovascular disease, dementia, Chronic pulmonary disease, liver disease, renal disease, hypertension, diabetes, sepsis, Charlson comorbidity index, OASIS, and SOFA).</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec017"><title>The analysis of inverted L-shaped association</title><p>Multivariable-adjusted RCS analyses suggested an inverted L-shaped association between AAR and 28-day mortality (P for non-linearity&#x02009;&#x0003c;&#x02009;0.0001, <xref rid="pone.0324904.g003" ref-type="fig">Fig 3</xref>). This trend was also observed for 60-day, 90-day, and 365-day mortality (<xref rid="pone.0324904.s006" ref-type="supplementary-material">S2 Fig</xref>). The inflection point was ascertained using a two-piecewise linear regression model, as shown in <xref rid="pone.0324904.t004" ref-type="table">Table 4</xref>. For an AAR less than 2.60, 28-day mortality increased with higher AAR (HR&#x02009;=&#x02009;1.19, 95% CI: 1.11&#x02013;1.27, P&#x02009;&#x0003c;&#x02009;0.001). Beyond the inflection point, the association became non-significant, with a horizontal curve (HR&#x02009;=&#x02009;1.02, 95% CI: 0.97&#x02013;1.06, P&#x02009;=&#x02009;0.498).</p><table-wrap position="float" id="pone.0324904.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0324904.t004</object-id><label>Table 4</label><caption><title>Threshold effect analysis of AAR and 28-day mortality.</title></caption><alternatives><graphic xlink:href="pone.0324904.t004" id="pone.0324904.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">AAR ratio</th><th align="left" colspan="2" rowspan="1">Adjusted Model</th></tr><tr><th align="left" rowspan="1" colspan="1">HR (95%CI)</th><th align="left" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x0003c; 2.60</td><td align="left" rowspan="1" colspan="1">1.19 (1.11&#x02009;~&#x02009;1.27)</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265; 2.60</td><td align="left" rowspan="1" colspan="1">1.02 (0.97&#x02009;~&#x02009;1.06)</td><td align="left" rowspan="1" colspan="1">0.498</td></tr><tr><td align="left" rowspan="1" colspan="1">Likelihood Ratio test</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr></tbody></table></alternatives></table-wrap><fig position="float" id="pone.0324904.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0324904.g003</object-id><label>Fig 3</label><caption><title>Restricted cubic spline regression analysis of AAR and 28-day mortality.</title><p>Only 99.9% of the data is shown. The median AAR was defined as the reference standard. The pink area represents the 95% CI. Adjusted for all factors in Model 4.</p></caption><graphic xlink:href="pone.0324904.g003" position="float"/></fig></sec><sec id="sec018"><title>Subgroup analysis</title><p>To delve deeper into the association between the AAR and 28-day mortality, we analyzed various subgroups, including gender, age, race, smoking status, SOFA score, Charlson comorbidity index, and conditions such as heart failure, coronary heart disease, cerebrovascular disease, chronic pulmonary disease, liver disease, renal disease, and diabetes (see <xref rid="pone.0324904.g004" ref-type="fig">Fig 4</xref>). These analyses demonstrated that the relationship was robust and reliable in all subgroups. Significant interactions were observed in the SOFA score tertiles, the Charlson comorbidity index tertiles, and between patients with and without diabetes. Among diabetic patients and those with a lower Charlson comorbidity index and SOFA scores, the AAR exerts a notably greater impact on 28-day mortality.</p><fig position="float" id="pone.0324904.g004"><object-id pub-id-type="doi">10.1371/journal.pone.0324904.g004</object-id><label>Fig 4</label><caption><title>Forest plots of stratified analyses of AAR and 28-day mortality.</title><p>Except for the stratification factor itself, each stratification factor was adjusted for all variables in Model 4.</p></caption><graphic xlink:href="pone.0324904.g004" position="float"/></fig></sec><sec id="sec019"><title>Sensitivity analysis</title><p><xref rid="pone.0324904.s003" ref-type="supplementary-material">S3 Table</xref> provides a detailed analysis of the baseline characteristics of the included patients in the eICU-CRD. After adjusting for all confounders, the AAR was significantly associated with in-hospital mortality (HR&#x02009;=&#x02009;1.04, 95% CI: 1.03&#x02013;1.05, P&#x02009;&#x0003c;&#x02009;0.001). Quartile analysis revealed a stepwise increase in mortality risk with higher AAR quartiles. Specifically, Q2 had an HR of 1.16 (95% CI: 1.06&#x02013;1.27), Q3 showed an HR of 1.28 (95% CI: 1.18&#x02013;1.39), and Q4 exhibited an HR of 1.51 (95% CI: 1.39&#x02013;1.64) (see <xref rid="pone.0324904.s004" ref-type="supplementary-material">S4 Table</xref>). These findings demonstrate the increasing risk of in-hospital mortality associated with higher AAR quartiles. Multivariable-adjusted RCS analyses suggested an inverted L-shaped association between AAR and in-hospital mortality in the eICU-CRD (P for non-linearity&#x02009;&#x0003c;&#x02009;0.0001, <xref rid="pone.0324904.s007" ref-type="supplementary-material">S3 Fig</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><p>This retrospective cohort study confirmed that AAR is a significant independent predictor of mortality in ICU patients. A pronounced inverted L-shaped relationship was delineated between AAR and 28-day mortality, with an inflection point at 2.6. Mortality increased with AAR below this threshold and plateaued above it. The study&#x02019;s subgroup and sensitivity analyses robustly affirm the correlation&#x02019;s reliability and potency concerning the 28-day mortality. The research introduces a straightforward and effective biomarker that can be used for swift identification and intervention in patients at high risk.</p><p>A previous study based on the NHANES database showed that in elderly American community-based individuals (age&#x02009;&#x02265;&#x02009;65 years), low levels of ALT and AST, along with high AAR, are associated with increased mortality, with AAR exhibiting the strongest predictive power for all-cause mortality [<xref rid="pone.0324904.ref008" ref-type="bibr">8</xref>]. Another study confirmed that a high AAR was an independent predictor of all-cause and cardiovascular mortality in a Japanese community-based population (age&#x02009;&#x0003e;&#x02009;40 years), outperforming AST and ALT as standalone indicators [<xref rid="pone.0324904.ref030" ref-type="bibr">30</xref>]. A recent investigation into critically ill elderly Americans (age&#x02009;&#x02265;&#x02009;65 years) uncovered a non-linear, saturation-based relationship between AAR and in-hospital mortality, with AAR levels below 1.80 correlating with increased mortality [<xref rid="pone.0324904.ref025" ref-type="bibr">25</xref>]. Our study, drawing from the MIMIC-IV database, includes a broader spectrum of critically ill patients, half of whom are under 65 years old. Analysis using RCS indicated an inverted L-shaped relationship between AAR and mortality at various time points (28-day, 60-day, 90-day, and 365-day) after adjusting for confounding factors. Elevated AAR levels, below the inflection point, were significantly and independently linked to higher mortality. Additionally, increased AAR levels were independently associated with an increased need for vasopressor support, ventilators, and prolonged ICU stays within 28 days. To our knowledge, this study is the first effort to definitively establish the AAR as a standalone mortality predictor in the adult ICU population.</p><p>Recent studies have also linked the elevated AAR to adverse outcomes in patients with various diseases. For instance, Maeda D. et al. reported a significant one-year mortality risk (HR&#x02009;=&#x02009;1.57, 95% CI: 1.02&#x02013;2.42) in the high AAR group compared to the low group in older Japanese heart failure patients [<xref rid="pone.0324904.ref013" ref-type="bibr">13</xref>]. Qin C. et al. found that in COVID-19 patients, an elevated AST/ALT ratio (&#x02265;1.38) at admission was linked to higher mortality risk and worse clinical status. Dynamic monitoring revealed that a sustained decrease in AAR during treatment suggests a favorable prognosis [<xref rid="pone.0324904.ref031" ref-type="bibr">31</xref>]. Another study linked higher AAR at stroke onset to increased 3-month and one-year mortality, as well as poor outcomes in patients with transient ischemic attack or acute ischemic stroke [<xref rid="pone.0324904.ref018" ref-type="bibr">18</xref>]. Zoppini G. et al. also discovered the AAR to be an independent risk factor for both all-cause and cardiovascular mortality in individuals with type 2 diabetes [<xref rid="pone.0324904.ref010" ref-type="bibr">10</xref>]. Our study extends these findings to critically ill ICU patients, conducting subgroup analyses based on the presence of conditions such as congestive heart failure, cerebrovascular disease, and diabetes. Notably, our subgroup analysis in patients with congestive heart failure (CHF) revealed results similar to those reported by Bian Y et al., who demonstrated that an elevated AAR within the first 24&#x02009;h of ICU admission is independently associated with increased 28-day mortality in critically ill patients with CHF (HR&#x02009;=&#x02009;1.18, 95% CI: 1.04&#x02013;1.34) [<xref rid="pone.0324904.ref024" ref-type="bibr">24</xref>]. Furthermore,we found that an elevated AAR is an independent predictor of 28-day mortality, particularly pronounced in diabetic patients and those with lower Charlson comorbidity index and SOFA scores. The possible reasons for this outcome could be that patients with higher SOFA scores or Charlson comorbidity index exhibit a greater number of risk factors affecting mortality, thereby diminishing the independent effect of AAR on death. Further investigation is necessary to validate these findings and to elucidate the specific mechanisms underlying this relationship.</p><p>The mechanisms linking elevated AAR to increased mortality in ICU patients are not fully understood, but several hypotheses have been proposed. First, heightened AAR levels may signal mitochondrial dysfunction, potentially leading to elevated oxidative stress. AST, found in both the cytoplasmic and mitochondrial compartments of hypermetabolic tissues, and ALT, primarily in the hepatocyte cytoplasm, play crucial roles in carbohydrate and protein metabolism and participate in the auxiliary metabolic pathways of glycolysis [<xref rid="pone.0324904.ref001" ref-type="bibr">1</xref>]. If there is mitochondrial dysfunction, tissues rich in AST may substantially release AST, potentially leading to an elevated AAR. Our study observed a higher incidence of myocardial infarction, congestive heart failure, coronary artery disease, liver disease, and renal disease in patients with elevated AAR. An animal study reported that rats with high AAR had lower aerobic capacity and increased oxidative stress biomarker activity [<xref rid="pone.0324904.ref032" ref-type="bibr">32</xref>]. Additionally, mitochondrial dysfunction and oxidative stress can impair immune function, predispose to infections, and augment the release of inflammatory mediators. This has been confirmed in an animal study where mice with an elevated AAR exhibited mitochondrial damage, heightened oxidative stress, and increased expression of inflammatory cytokines IL-1&#x003b2; and IL-18 [<xref rid="pone.0324904.ref033" ref-type="bibr">33</xref>]. Furthermore, another study found a significant link between increased AAR and the levels of inflammatory cytokines such as IL-4, IL-6, and TNF-&#x003b1; in type 2 diabetes [<xref rid="pone.0324904.ref034" ref-type="bibr">34</xref>]. Our study also noted a higher incidence of sepsis in patients with higher AAR. Second, elevated AAR levels could indicate increased glycolysis. A meta-analysis links high preoperative AAR in urothelial carcinoma patients to poor outcomes, suggesting heightened glycolysis in tumor cells [<xref rid="pone.0324904.ref021" ref-type="bibr">21</xref>]. Critical illness often induces a hypermetabolic state, and when mitochondrial function is impaired, cells may compensate for the deficiency in ATP production by enhancing glycolysis, which may subsequently lead to metabolic imbalances and other adverse conditions. Third, elevated AAR levels could point toward frailty and sarcopenia. Research has demonstrated a significant relationship between elevated AAR and sarcopenia, which is common in ICU patients and associated with higher mortality in critical illness [<xref rid="pone.0324904.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0324904.ref022" ref-type="bibr">22</xref>]. However, the precise mechanisms linking AAR to mortality in ICU patients require further investigation.</p><p>This research is strengthened by several advantages, including its expansive sample size, extended follow-up duration, adjustments for a variety of significant risk factors and possible confounding factors, and a thorough examination of AAR&#x02019;s association with mortality, as well as its impact across various subgroups. Furmore, the use of an external validation cohort from the eICU-CRD enhanced the generalizability and robustness of the study. Nonetheless, there are limitations to consider. Firstly, its retrospective approach is vulnerable to selection and ascertainment bias, despite the use of a multivariable Cox regression model to ensure analytical rigor. Secondly, the lack of detailed cause-of-death information in the MIMIC-IV database hinders a more nuanced competing risks analysis. Thirdly, the effectiveness of interventions aimed at modifying AST/ALT levels for better patient outcomes remains unclear. Hence, our results require confirmation from well-conducted, multi-center, and prospective studies.</p></sec><sec sec-type="conclusions" id="sec021"><title>Conclusion</title><p>Our study has confirmed AAR as a crucial indicator for predicting the 28-day mortality among ICU patients, with this predictive ability extending across diverse patient subgroups. Furthermore, an inverted L-shaped correlation was identified between AAR and the risk of 28-day, 60-day, 90-day, and 365-day mortality for ICU patients. This finding suggests that AAR may serve as a robust biomarker for patient risk stratification and could inform clinical decision making within the ICU setting.</p></sec><sec id="sec022" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0324904.s001" position="float" content-type="local-data"><label>S1 Table</label><caption><title>Univariate regression analysis of covariates and 28-day mortality in the MIMIC-IV database.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324904.s001.docx"/></supplementary-material><supplementary-material id="pone.0324904.s002" position="float" content-type="local-data"><label>S2 Table</label><caption><title>Sensitivity analysis of AAR and 28-day mortality in the MIMIC-IV database.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324904.s002.docx"/></supplementary-material><supplementary-material id="pone.0324904.s003" position="float" content-type="local-data"><label>S3 Table</label><caption><title>Baseline characteristics of the included patients in the eICU-CRD.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324904.s003.docx"/></supplementary-material><supplementary-material id="pone.0324904.s004" position="float" content-type="local-data"><label>S4 Table</label><caption><title>Cox model analysis of AAR and In-hospital mortality in the eICU-CRD.</title><p>(DOCX)</p></caption><media xlink:href="pone.0324904.s004.docx"/></supplementary-material><supplementary-material id="pone.0324904.s005" position="float" content-type="local-data"><label>S1 Fig</label><caption><title>Flowchart of the patient selection in the eICU-CRD.</title><p>(TIF)</p></caption><media xlink:href="pone.0324904.s005.tif"/></supplementary-material><supplementary-material id="pone.0324904.s006" position="float" content-type="local-data"><label>S2 Fig</label><caption><title>RCS regression analysis of AAR with 60-day (a), 90-day (b) and 365-day (c) mortality in the MIMIC-IV database.</title><p>Only 99.9% of the data is shown. The median AAR was defined as the reference standard. The pink area represents the 95% CI. Adjusted for all factors in Model 4.</p><p>(TIF)</p></caption><media xlink:href="pone.0324904.s006.tif"/></supplementary-material><supplementary-material id="pone.0324904.s007" position="float" content-type="local-data"><label>S3 Fig</label><caption><title>RCS regression analysis of AAR and in-hospital mortality in the eICU-CRD.</title><p>Only 99.9% of the data is shown. The median AAR was defined as the reference standard. The pink area represents the 95% CI. Adjusted for all factors in Model 4.</p><p>(TIF)</p></caption><media xlink:href="pone.0324904.s007.tif"/></supplementary-material></sec></body><back><ack><p>We are grateful to Dr. Qilin Yang (Department of Critical Care, The Second Affiliated Hospital of Guangzhou Medical University) for his valuable support in the installation and application of the MIMIC database. We also extend our thanks to Dr. Jie Liu (Department of Vascular and Endovascular Surgery, People&#x02019;s Liberation Army of China General Hospital) for his valuable advice on statistical analysis.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>AAR</term><def><p>aspartate aminotransferase to alanine aminotransferase ratio</p></def></def-item><def-item><term>AST</term><def><p>aspartate aminotransferase</p></def></def-item><def-item><term>ALT</term><def><p>alanine aminotransferase</p></def></def-item><def-item><term>Q</term><def><p>quartile</p></def></def-item><def-item><term>RCS</term><def><p>restricted cubic splines</p></def></def-item><def-item><term>MIMIC-IV</term><def><p>Medical Information Mart for Intensive Care IV</p></def></def-item><def-item><term>HR</term><def><p>hazard ratios</p></def></def-item><def-item><term>CI</term><def><p>confidence intervals</p></def></def-item><def-item><term>bpm</term><def><p>beats per minute</p></def></def-item><def-item><term>SBP</term><def><p>systolic blood pressure</p></def></def-item><def-item><term>DBP</term><def><p>diastolic blood pressure</p></def></def-item><def-item><term>WBC</term><def><p>white blood cell</p></def></def-item><def-item><term>BUN</term><def><p>blood urea nitrogen</p></def></def-item><def-item><term>PT</term><def><p>prothrombin time</p></def></def-item><def-item><term>SOFA</term><def><p>sequential organ failure assessment</p></def></def-item><def-item><term>OASIS</term><def><p>Oxford acute severity of illness score</p></def></def-item><def-item><term>IQR</term><def><p>interquartile range</p></def></def-item><def-item><term>VIF</term><def><p>variance inflation factor</p></def></def-item><def-item><term>ICU</term><def><p>intensive care unit</p></def></def-item><def-item><term>COVID-19</term><def><p>coronavirus disease 2019</p></def></def-item><def-item><term>STROBE</term><def><p>Strengthening the Reporting of Observational studies in Epidemiology</p></def></def-item><def-item><term>ICD</term><def><p>International Classification of Diseases</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pone.0324904.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Botros</surname><given-names>M</given-names></name>, <name><surname>Sikaris</surname><given-names>K</given-names></name>. <article-title>The de Ritis ratio: The test of time</article-title>. <source>Clin Biochem Rev</source>. <year>2013</year>;<volume>34</volume>(<issue>3</issue>):<fpage>117</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">24353357</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>De Ritis</surname><given-names>F</given-names></name>, <name><surname>Coltorti</surname><given-names>M</given-names></name>, <name><surname>Giusti</surname><given-names>G</given-names></name>. <article-title>An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities</article-title>. <source>Clin Chim Acta</source>. <year>1957</year>;<volume>2</volume>(<issue>1</issue>):<fpage>70</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0009-8981(57)90027-x</pub-id>
<pub-id pub-id-type="pmid">13447217</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Sorbi</surname><given-names>D</given-names></name>, <name><surname>Boynton</surname><given-names>J</given-names></name>, <name><surname>Lindor</surname><given-names>KD</given-names></name>. <article-title>The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease</article-title>. <source>Am J Gastroenterol</source>. <year>1999</year>;<volume>94</volume>(<issue>4</issue>):<fpage>1018</fpage>&#x02013;<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1572-0241.1999.01006.x</pub-id>
<pub-id pub-id-type="pmid">10201476</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>G</given-names></name>, <name><surname>Jones</surname><given-names>DB</given-names></name>, <name><surname>Katelaris</surname><given-names>P</given-names></name>. <article-title>Value of AST/ALT ratio as fibrotic predictor in chronic hepatitis C</article-title>. <source>Am J Gastroenterol</source>. <year>2005</year>;<volume>100</volume>(<issue>7</issue>):<fpage>1623</fpage>&#x02013;<lpage>4; author reply 1624</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.50006_6.x</pub-id>
<pub-id pub-id-type="pmid">15984996</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Nyblom</surname><given-names>H</given-names></name>, <name><surname>Nordlinder</surname><given-names>H</given-names></name>, <name><surname>Olsson</surname><given-names>R</given-names></name>. <article-title>High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis</article-title>. <source>Liver International</source>. <year>2007</year>;<volume>27</volume>(<issue>5</issue>):<fpage>694</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1478-3231.2007.01471.x</pub-id><pub-id pub-id-type="pmid">17498256</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Hofmeister</surname><given-names>MG</given-names></name>, <name><surname>Xing</surname><given-names>J</given-names></name>, <name><surname>Foster</surname><given-names>MA</given-names></name>, <name><surname>Augustine</surname><given-names>RJ</given-names></name>, <name><surname>Burkholder</surname><given-names>C</given-names></name>, <name><surname>Collins</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Factors Associated With Hepatitis A Mortality During Person-to-Person Outbreaks: A Matched Case-Control Study-United States, 2016-2019</article-title>. <source>Hepatology</source>. <year>2021</year>;<volume>74</volume>(<issue>1</issue>):<fpage>28</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/hep.31645</pub-id>
<pub-id pub-id-type="pmid">33217769</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>Q</given-names></name>, <name><surname>Zhou</surname><given-names>C-Y</given-names></name>, <name><surname>Sun</surname><given-names>H-X</given-names></name>, <name><surname>Lin</surname><given-names>Y-S</given-names></name>, <name><surname>Jiao</surname><given-names>X-F</given-names></name>, <etal>et al</etal>. <article-title>Association of AST/ALT (De Ritis) ratio with sarcopenia in a Chinese population of community-dwelling elderly</article-title>. <source>Heliyon</source>. <year>2023</year>;<volume>9</volume>(<issue>10</issue>):e20427. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e20427</pub-id>
<pub-id pub-id-type="pmid">37822616</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Ke</surname><given-names>P</given-names></name>, <name><surname>Zhong</surname><given-names>L</given-names></name>, <name><surname>Peng</surname><given-names>W</given-names></name>, <name><surname>Xu</surname><given-names>M</given-names></name>, <name><surname>Feng</surname><given-names>J</given-names></name>, <name><surname>Tian</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Association of the serum transaminase with mortality among the US elderly population</article-title>. <source>J Gastroenterol Hepatol</source>. <year>2022</year>;<volume>37</volume>(<issue>5</issue>):<fpage>946</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/jgh.15815</pub-id>
<pub-id pub-id-type="pmid">35233823</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Ding</surname><given-names>C</given-names></name>, <name><surname>Hu</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Zhou</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>The association between AST/ALT ratio and all-cause and cardiovascular mortality in patients with hypertension</article-title>. <source>Medicine (Baltimore)</source>. <year>2021</year>;<volume>100</volume>(<issue>31</issue>):e26693. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MD.0000000000026693</pub-id>
<pub-id pub-id-type="pmid">34397804</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Zoppini</surname><given-names>G</given-names></name>, <name><surname>Cacciatori</surname><given-names>V</given-names></name>, <name><surname>Negri</surname><given-names>C</given-names></name>, <name><surname>Stoico</surname><given-names>V</given-names></name>, <name><surname>Lippi</surname><given-names>G</given-names></name>, <name><surname>Targher</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes</article-title>. <source>Medicine (Baltimore)</source>. <year>2016</year>;<volume>95</volume>(<issue>43</issue>):e4821. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MD.0000000000004821</pub-id>
<pub-id pub-id-type="pmid">27787357</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>P-Y</given-names></name>, <name><surname>Yao</surname><given-names>R-Q</given-names></name>, <name><surname>Ren</surname><given-names>C</given-names></name>, <name><surname>Li</surname><given-names>S-Y</given-names></name>, <name><surname>Li</surname><given-names>Y-X</given-names></name>, <name><surname>Zhu</surname><given-names>S-Y</given-names></name>, <etal>et al</etal>. <article-title>De Ritis Ratio as a Significant Prognostic Factor in Patients with Sepsis: A Retrospective Analysis</article-title>. <source>J Surg Res</source>. <year>2021</year>;<volume>264</volume>:<fpage>375</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jss.2021.03.018</pub-id>
<pub-id pub-id-type="pmid">33848836</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Zinellu</surname><given-names>A</given-names></name>, <name><surname>Arru</surname><given-names>F</given-names></name>, <name><surname>De Vito</surname><given-names>A</given-names></name>, <name><surname>Sassu</surname><given-names>A</given-names></name>, <name><surname>Valdes</surname><given-names>G</given-names></name>, <name><surname>Scano</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients</article-title>. <source>Eur J Clin Invest</source>. <year>2021</year>;<volume>51</volume>(<issue>1</issue>):e13427. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/eci.13427</pub-id>
<pub-id pub-id-type="pmid">33043447</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Maeda</surname><given-names>D</given-names></name>, <name><surname>Kagiyama</surname><given-names>N</given-names></name>, <name><surname>Jujo</surname><given-names>K</given-names></name>, <name><surname>Saito</surname><given-names>K</given-names></name>, <name><surname>Kamiya</surname><given-names>K</given-names></name>, <name><surname>Saito</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Aspartate aminotransferase to alanine aminotransferase ratio is associated with frailty and mortality in older patients with heart failure</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>11957</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-021-91368-z</pub-id>
<pub-id pub-id-type="pmid">34099767</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Ndrepepa</surname><given-names>G</given-names></name>, <name><surname>Holdenrieder</surname><given-names>S</given-names></name>, <name><surname>Kastrati</surname><given-names>A</given-names></name>. <article-title>Prognostic value of De Ritis ratio in patients with acute myocardial infarction</article-title>. <source>Clin Chim Acta</source>. <year>2022</year>;<volume>535</volume>:<fpage>75</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cca.2022.08.016</pub-id>
<pub-id pub-id-type="pmid">35985502</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Chen</surname><given-names>Z</given-names></name>, <name><surname>Zeng</surname><given-names>D</given-names></name>, <name><surname>Ran</surname><given-names>M</given-names></name>. <article-title>Impact of the De Ritis Ratio on the Prognosis of Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention</article-title>. <source>Med Sci Monit</source>. <year>2022</year>;<volume>28</volume>:e937737. <comment>doi: </comment><pub-id pub-id-type="doi">10.12659/MSM.937737</pub-id>
<pub-id pub-id-type="pmid">36544363</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>B</given-names></name>, <name><surname>Hu</surname><given-names>L</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Zhu</surname><given-names>B</given-names></name>, <name><surname>Kong</surname><given-names>W</given-names></name>, <name><surname>Zhu</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Aspartate transaminase/alanine transaminase (De Ritis ratio) predicts survival in major burn patients</article-title>. <source>Burns</source>. <year>2022</year>;<volume>48</volume>(<issue>4</issue>):<fpage>872</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.burns.2021.08.006</pub-id>
<pub-id pub-id-type="pmid">34456097</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Tsai</surname><given-names>C-H</given-names></name>, <name><surname>Rau</surname><given-names>C-S</given-names></name>, <name><surname>Chou</surname><given-names>S-E</given-names></name>, <name><surname>Su</surname><given-names>W-T</given-names></name>, <name><surname>Hsu</surname><given-names>S-Y</given-names></name>, <name><surname>Hsieh</surname><given-names>C-H</given-names></name>. <article-title>Delta De Ritis Ratio Is Associated with Worse Mortality Outcomes in Adult Trauma Patients with Moderate-to-Severe Traumatic Brain Injuries</article-title>. <source>Diagnostics (Basel)</source>. <year>2022</year>;<volume>12</volume>(<issue>12</issue>):<fpage>3004</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/diagnostics12123004</pub-id>
<pub-id pub-id-type="pmid">36553011</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Tian</surname><given-names>X</given-names></name>, <name><surname>Zuo</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Aspartate aminotransferase to alanine aminotransferase ratio and clinical outcomes after acute ischemic stroke: the CNSR-III registry</article-title>. <source>Intern Emerg Med</source>. <year>2022</year>;<volume>17</volume>(<issue>7</issue>):<fpage>1987</fpage>&#x02013;<lpage>96</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11739-022-03059-w</pub-id>
<pub-id pub-id-type="pmid">35986833</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Rief</surname><given-names>P</given-names></name>, <name><surname>Pichler</surname><given-names>M</given-names></name>, <name><surname>Raggam</surname><given-names>R</given-names></name>, <name><surname>Hafner</surname><given-names>F</given-names></name>, <name><surname>Gerger</surname><given-names>A</given-names></name>, <name><surname>Eller</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>The AST/ALT (De-Ritis) ratio: A novel marker for critical limb ischemia in peripheral arterial occlusive disease patients</article-title>. <source>Medicine (Baltimore)</source>. <year>2016</year>;<volume>95</volume>(<issue>24</issue>):e3843. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/MD.0000000000003843</pub-id>
<pub-id pub-id-type="pmid">27310963</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Zhou</surname><given-names>L</given-names></name>, <name><surname>Zhou</surname><given-names>J</given-names></name>, <name><surname>He</surname><given-names>L</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Elevated AST/ALT ratio is associated with all-cause mortality and cancer incident</article-title>. <source>J Clin Lab Anal</source>. <year>2022</year>;<volume>36</volume>(<issue>5</issue>):e24356. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/jcla.24356</pub-id>
<pub-id pub-id-type="pmid">35318741</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Hu</surname><given-names>X</given-names></name>, <name><surname>Yang</surname><given-names>W-X</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Shao</surname><given-names>Y-X</given-names></name>, <name><surname>Xiong</surname><given-names>S-C</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>. <article-title>The prognostic value of De Ritis (AST/ALT) ratio in patients after surgery for urothelial carcinoma: a systematic review and meta-analysis</article-title>. <source>Cancer Cell Int</source>. <year>2020</year>;<volume>20</volume>:<fpage>39</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12935-020-1125-2</pub-id>
<pub-id pub-id-type="pmid">32042266</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>X-M</given-names></name>, <name><surname>Chen</surname><given-names>D</given-names></name>, <name><surname>Xie</surname><given-names>X-H</given-names></name>, <name><surname>Zhang</surname><given-names>J-E</given-names></name>, <name><surname>Zeng</surname><given-names>Y</given-names></name>, <name><surname>Cheng</surname><given-names>AS</given-names></name>. <article-title>Sarcopenia as a predictor of mortality among the critically ill in an intensive care unit: a systematic review and meta-analysis</article-title>. <source>BMC Geriatr</source>. <year>2021</year>;<volume>21</volume>(<issue>1</issue>):<fpage>339</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12877-021-02276-w</pub-id>
<pub-id pub-id-type="pmid">34078275</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>Z</given-names></name>, <name><surname>Ma</surname><given-names>G</given-names></name>, <name><surname>Chen</surname><given-names>L</given-names></name>. <article-title>De-Ritis Ratio Is Associated with Mortality after Cardiac Arrest</article-title>. <source>Dis Markers</source>. <year>2020</year>;<volume>2020</volume>:<fpage>8826318</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2020/8826318</pub-id>
<pub-id pub-id-type="pmid">33204363</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Bian</surname><given-names>Y</given-names></name>, <name><surname>Kou</surname><given-names>H</given-names></name>, <name><surname>Jia</surname><given-names>Z</given-names></name>, <name><surname>Cui</surname><given-names>Q</given-names></name>, <name><surname>Wu</surname><given-names>P</given-names></name>, <name><surname>Ma</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Association between aspartate aminotransferase to alanine aminotransferase ratio and mortality in critically ill patients with congestive heart failure</article-title>. <source>Sci Rep</source>. <year>2024</year>;<volume>14</volume>(<issue>1</issue>):<fpage>26317</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-024-77141-y</pub-id>
<pub-id pub-id-type="pmid">39487164</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Meng</surname><given-names>L</given-names></name>, <name><surname>Xin</surname><given-names>S</given-names></name>, <name><surname>Chang</surname><given-names>C</given-names></name>, <name><surname>Zhao</surname><given-names>X</given-names></name>, <name><surname>Guo</surname><given-names>B</given-names></name>. <article-title>Non-linear association between aspartate aminotransferase to alanine aminotransferase ratio and mortality in critically ill older patients: A retrospective cohort study</article-title>. <source>PLoS One</source>. <year>2023</year>;<volume>18</volume>(<issue>11</issue>):e0293749. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0293749</pub-id>
<pub-id pub-id-type="pmid">37917784</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>A</given-names></name>, <name><surname>Bulgarelli</surname><given-names>L</given-names></name>, <name><surname>Pollard</surname><given-names>T</given-names></name>, <name><surname>Horng</surname><given-names>S</given-names></name>, <name><surname>Celi</surname><given-names>LA</given-names></name>, <name><surname>Mark</surname><given-names>R</given-names></name>. <article-title>MIMIC-IV (version 2.2). PhysioNet</article-title>. <year>2023</year>. <source>Available from</source>: <comment>doi: </comment><pub-id pub-id-type="doi">10.13026/6mm1-ek67</pub-id></mixed-citation></ref><ref id="pone.0324904.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>AEW</given-names></name>, <name><surname>Bulgarelli</surname><given-names>L</given-names></name>, <name><surname>Shen</surname><given-names>L</given-names></name>, <name><surname>Gayles</surname><given-names>A</given-names></name>, <name><surname>Shammout</surname><given-names>A</given-names></name>, <name><surname>Horng</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>MIMIC-IV, a freely accessible electronic health record dataset</article-title>. <source>Sci Data</source>. <year>2023</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41597-022-01899-x</pub-id>
<pub-id pub-id-type="pmid">36596836</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Pollard</surname><given-names>T</given-names></name>, <name><surname>Johnson</surname><given-names>A</given-names></name>, <name><surname>Raffa</surname><given-names>J</given-names></name>, <name><surname>Celi</surname><given-names>LA</given-names></name>, <name><surname>Badawi</surname><given-names>O</given-names></name>, <name><surname>Mark</surname><given-names>R</given-names></name>. <article-title>eICU Collaborative Research Database (version 2.0). PhysioNet</article-title>. <year>2019</year>. Available from: <comment>doi: </comment><pub-id pub-id-type="doi">10.13026/C2WM1R</pub-id></mixed-citation></ref><ref id="pone.0324904.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Pollard</surname><given-names>TJ</given-names></name>, <name><surname>Johnson</surname><given-names>AEW</given-names></name>, <name><surname>Raffa</surname><given-names>JD</given-names></name>, <name><surname>Celi</surname><given-names>LA</given-names></name>, <name><surname>Mark</surname><given-names>RG</given-names></name>, <name><surname>Badawi</surname><given-names>O</given-names></name>. <article-title>The eICU Collaborative Research Database, a freely available multi-center database for critical care research</article-title>. <source>Sci Data</source>. <year>2018</year>;<volume>5</volume>:<fpage>180178</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sdata.2018.178</pub-id>
<pub-id pub-id-type="pmid">30204154</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Yokoyama</surname><given-names>M</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Otaki</surname><given-names>Y</given-names></name>, <name><surname>Takahashi</surname><given-names>H</given-names></name>, <name><surname>Arimoto</surname><given-names>T</given-names></name>, <name><surname>Shishido</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Association of the Aspartate Aminotransferase to Alanine Aminotransferase Ratio with BNP Level and Cardiovascular Mortality in the General Population: The Yamagata Study 10-Year Follow-Up</article-title>. <source>Dis Markers</source>. <year>2016</year>;<volume>2016</volume>:<fpage>4857917</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2016/4857917</pub-id>
<pub-id pub-id-type="pmid">27872510</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Qin</surname><given-names>C</given-names></name>, <name><surname>Wei</surname><given-names>Y</given-names></name>, <name><surname>Lyu</surname><given-names>X</given-names></name>, <name><surname>Zhao</surname><given-names>B</given-names></name>, <name><surname>Feng</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>High aspartate aminotransferase to alanine aminotransferase ratio on admission as risk factor for poor prognosis in COVID-19 patients</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>16496</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-020-73575-2</pub-id>
<pub-id pub-id-type="pmid">33020546</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Botezelli</surname><given-names>JD</given-names></name>, <name><surname>Cambri</surname><given-names>LT</given-names></name>, <name><surname>Ghezzi</surname><given-names>AC</given-names></name>, <name><surname>Dalia</surname><given-names>RA</given-names></name>, <name><surname>Voltarelli</surname><given-names>FA</given-names></name>, <name><surname>de Mello</surname><given-names>MAR</given-names></name>. <article-title>Fructose-rich diet leads to reduced aerobic capacity and to liver injury in rats</article-title>. <source>Lipids Health Dis</source>. <year>2012</year>;<volume>11</volume>:<fpage>78</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1476-511X-11-78</pub-id>
<pub-id pub-id-type="pmid">22713601</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Mu</surname><given-names>Y</given-names></name>, <name><surname>Sun</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Liu</surname><given-names>Z</given-names></name>, <name><surname>Li</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Activation of pyroptosis and ferroptosis is involved in the hepatotoxicity induced by polystyrene microplastics in mice</article-title>. <source>Chemosphere</source>. <year>2022</year>;<volume>291</volume>(Pt 2):<fpage>132944</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chemosphere.2021.132944</pub-id>
<pub-id pub-id-type="pmid">34793849</pub-id>
</mixed-citation></ref><ref id="pone.0324904.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>J</given-names></name>, <name><surname>Shi</surname><given-names>X</given-names></name>, <name><surname>Pan</surname><given-names>Y</given-names></name>. <article-title>The Association of Aspartate Aminotransferase/Alanine Aminotransferase Ratio with Diabetic Nephropathy in Patients with Type 2 Diabetes</article-title>. <source>Diabetes Metab Syndr Obes</source>. <year>2021</year>;<volume>14</volume>:<fpage>3831</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2147/DMSO.S330741</pub-id>
<pub-id pub-id-type="pmid">34522109</pub-id>
</mixed-citation></ref></ref-list></back></article>